EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 19 / Numéro 8-9 (Août-Septembre 2003) Med Sci (Paris), 19 8-9 (2003) 878-884 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 19, Numéro 8-9, Août-Septembre 2003
Page(s) 878 - 884
Section Repères : Histoire Et Sciences Sociales
DOI https://doi.org/10.1051/medsci/20031989878
Publié en ligne 15 août 2003
  1. Bajos N, Bozon M, Ferrand A, Giami A, Spira A et le groupe ACSF. La sexualité aux temps du Sida. Paris: PUF, 1998. [Google Scholar]
  2. Delor F, Hubert M. Revisiting the concept of vulnerability. Soc Sci Med 2000; 50: 1557–70. [Google Scholar]
  3. Pierret J. Everyday life with AIDS/HIV: surveys in the social sciences. Soc Sci Med 2000; 50: 1589–98. [Google Scholar]
  4. Moatti JP, Souteyrand Y. HIV/AIDS social and behavioural research: past advances and thoughts about the future. Soc Sci Med 2000; 50: 1519–32 [Google Scholar]
  5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21–30. [Google Scholar]
  6. Bangsberg DR, Perry S, Charlebois ED, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15: 1181–3. [Google Scholar]
  7. Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279: 1977–83. [Google Scholar]
  8. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 435–42. [Google Scholar]
  9. Duran S, Solas C, Spire B, et al. Do HIV-infected injecting drug users overreport adherence to highly active antiretroviral therapy ? A comparison between patients’ selfreports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 2001; 15: 1075–7. [Google Scholar]
  10. Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother 2001; 35: 1010–5. [Google Scholar]
  11. Chesney MA, Ickovics JR, Chambers DB, et al. Selfreported adherence to antiretroviral medications among participants in HIV clinical trials: the AIDS clinical trials group (AACTG) adherence instruments. AIDS Care 2000; 12: 255–66. [Google Scholar]
  12. Moatti JP, Spire B, Duran S. Un bilan des recherches socio-comportementales sur l’observance des traitements dans l’infection à VIH: au delà des modèles biomédicaux ? Rev Epidemiol Santé Publ 2000; 48: 182–9. [Google Scholar]
  13. Gordillo V, del Amo J, Soriano V, González-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763–9. [Google Scholar]
  14. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIVinfected patients: from a predictive to a dynamic approach. Soc Sci Med 2002; 54: 1481–96. [Google Scholar]
  15. Ammassari A, Murri R, Pezzotti P, et al. Selfreported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445–9. [Google Scholar]
  16. Duran S, Savès M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15: 2441–4. [Google Scholar]
  17. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French national APROCO cohort. J Acquir Immune Defic Syndr 2001; 28: 232–9. [Google Scholar]
  18. Nieuwkerk PT, Gisolf EH, Reijers MH, et al. Longterm quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001; 15: 1985–91. [Google Scholar]
  19. Low-Beer S, Chan K, Wood E, et al. Health related quality of life among persons with HIV after the use of protease inhibitors. Qual Life Res 2000; 9: 941–9. [Google Scholar]
  20. Carrieri MP, Spire B, Duran S, et al. Health-related quality of life after one year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32: 38–47. [Google Scholar]
  21. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547–9 [Google Scholar]
  22. Carrieri MP, Moatti JP, Vlahov D, et al. Access to antiretroviral treatment among French HIV-infected injection drug users (IDUs); the influence of continued drug use. J Epidemiol Community Health 1999; 53: 4–8. [Google Scholar]
  23. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIVinfected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000; 14: 151–5. [Google Scholar]
  24. Delfraissy JF. Prise en charge des personnes infectées par le VIH. Recommandations du groupe d’experts. Rapport 2002. Paris: Médecine-Sciences/Flammarion, 2002. [Google Scholar]
  25. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. JAcquir Immune Defic Syndr 2000; 25: 221–8. [Google Scholar]
  26. Hellinger FJ, Fleishman J A. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune DeficSyndr 2000; 24: 182–8. [Google Scholar]
  27. Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV cohort study. AIDS 1999; 13: 1115–22. [Google Scholar]
  28. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. HIVcost and services utilization study consortium. N Engl J Med 2001; 344: 817–23. [Google Scholar]
  29. Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir ImmuneDefic Syndr 2001; 27: 14–9. [Google Scholar]
  30. Garber A, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Eco 1997; 16: 1–31. [Google Scholar]
  31. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. NEngl J Med 2001; 344: 824–31. [Google Scholar]
  32. Vernay-Vaisse C, Enel P, Ben Diane MK, Rey D, Carrieri MP, Obadia Y. Facteurs associés à la découverte de la séropositivité au VIH à un stade d’immunodépression avancé. BEH 2002; 15: 61–3. [Google Scholar]
  33. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am JPubl Health 2001; 91: 1060–8. [Google Scholar]
  34. Ezzy D, De Visser R, Bartos M. Poverty, disease progression and employment among people living with HIV/AIDS in Australia. AIDS Care 1999; 11: 405–14. [Google Scholar]
  35. Obadia Y, Marimoutou C, Bouhnik AD, Lert F, Dray-Spira R, Bousquet F. Les aides apportées aux personnes atteintes par l’infection à VIH-SIDA: une enquête auprès des patients des services de soins en Île-de-France et en Provence-Alpes-Côte d’Azur. Etudes et Résultats. Paris: DREES, 2002; n°203. [Google Scholar]
  36. Piketty C, Castiel P, Giral P, et al. Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users. AIDS Care 1999; 11: 429–36. [Google Scholar]
  37. Fabre G, Tchobanian S. Les tensions actuelles entre le VIH et l’emploi. Sciences Sociales et Santé 2001; 19: 43–66. [Google Scholar]
  38. Colson AE, Keller Marla J, Sax PE, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30: 27–32. [Google Scholar]
  39. Schiltz MA, Sandfort TG. HIVpositive people, risk and sexual behaviour. Soc Sci Med 2000; 50: 1571–88. [Google Scholar]
  40. Lert F. Advances in HIV treatment and prevention: should treatment optimism lead to prevention pessimism ? AIDS Care 2000; 12: 745–55. [Google Scholar]
  41. Dukers NH, Spaargaren J, Geskus RB, Beijnen J, Coutinho RA, Fennema HS.HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS 2002; 16: 19–24. [Google Scholar]
  42. Adam P, Delmas MC, Brunet JB. Impact des nouveaux traitements antirétroviraux sur les attitudes et les comportements prêventives des lecteurs de la presse gay. De l’impact perçu par les individus à la mesure d’une influence effective. In: Lert F, Souteyrand Y, eds. Séropositivité, vie sexuelle et risque de transmission du VIH. Collection Sciences Sociales et Sida, Paris: Agence Nationale de Recherche sur le Sida. 1999: 43–53. [Google Scholar]
  43. Johnson AM, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358: 1835–42. [Google Scholar]
  44. Do AN, Hanson DL, Dworkin MS, Jones JL. Risk factors for and trends in gonorrhea incidence among persons infected with HIV in the United States. AIDS 2001; 15: 1149–55. [Google Scholar]
  45. Van de Ven P, Kippax S, Knox S, Prestage G, Crawford J. HIV treatments optimism and sexual behaviour among gay men in Sydney and Melbourne. AIDS 1999; 13: 2289–94. [Google Scholar]
  46. Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet 2001; 357: 432–5. [Google Scholar]
  47. Bouhnik AD, Moatti JP, Vlahov D, et al. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. J Epidemiol Commun Health 2002; 56: 349–53. [Google Scholar]
  48. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2000; 15: 1287–94. [Google Scholar]
  49. Bayer R. Clinical progress and the future of HIV exceptionalism. Arch Intern Med 1999; 159: 1042–8. [Google Scholar]
  50. Rosenbrock R, Dubois-Arber F, Moers M, Pinell P, Schaeffer D, Setbon M. The normalization of AIDS in Western European countries. Soc Sci Med 2000; 50: 1607–29. [Google Scholar]
  51. Landman R, Moatti JP, Perrin V, Huard P and the PAMPA Study Group. Variability of attitudes toward early initiation of HAART for HIV infection: a study of French prescribing physicians. AIDS Care 2000; 12: 711–6. [Google Scholar]
  52. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA 2001; 285: 1466–74. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.